Telomir Pharmaceuticals (NASDAQ: TELO) reported new research findings demonstrating that its lead compound, Telomir-Zn, produced growth inhibition across human and canine osteosarcoma cell-line models at similar low drug concentrations. The study was conducted at The Ohio State University College of Veterinary Medicine under the direction of Shay Bracha, DVM, MS, DACVIM (Oncology).
The research evaluated Telomir-Zn in one human and two canine osteosarcoma models. According to the company, the results support further translational investigation and a potential development pathway using naturally occurring canine osteosarcoma. Telomir is in discussions with The Ohio State University College of Veterinary Medicine and is assessing next steps for a potential in vivo efficacy study in canine osteosarcoma. Such a study could support both veterinary development and translational advancement toward human osteosarcoma.
Osteosarcoma is a challenging cancer with limited treatment options, particularly in advanced stages. The finding that Telomir-Zn inhibits growth in both human and canine models at similar concentrations is significant because it suggests a conserved mechanism that could be relevant across species. Canine osteosarcoma occurs naturally in dogs and shares many clinical and molecular features with human osteosarcoma, making it a valuable model for drug development.
Telomir Pharmaceuticals is a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer. The company’s lead program, Telomir-Zn, is designed to modulate intracellular metal homeostasis and epigenetic regulation. It has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration for a Phase 1/2 clinical trial in patients with advanced or metastatic triple-negative breast cancer.
Despite the promising osteosarcoma data, Telomir said its immediate focus remains its triple-negative breast cancer program, which is advancing toward site initiation and Phase 1/2 patient enrollment under the active FDA-cleared IND. This prioritization indicates that while the osteosarcoma findings are encouraging, the company is strategically directing resources toward its most advanced program.
For investors and industry observers, the news highlights Telomir’s broader pipeline potential beyond its lead indication. If the canine osteosarcoma study proceeds and yields positive results, it could provide a faster, lower-cost route to generate efficacy data that might inform human trials. The use of naturally occurring canine osteosarcoma as a translational model is gaining traction in oncology drug development, and Telomir’s exploration of this pathway could position it at the forefront of this approach.
To view the full press release, visit https://nnw.fm/laeGH. The latest news and updates relating to TELO are available in the company’s newsroom at https://nnw.fm/TELO.
